BMRN FY 2022 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.1B+13.5% YoY

Gross Profit

$1.6B76.0% margin

Operating Income

$161M7.7% margin

Net Income

$142M6.8% margin

EPS (Diluted)

$0.75

Cash Flow

Operating Cash Flow

$176M

Free Cash Flow

$55M

Stock-Based Comp.

$196M

Balance Sheet

Total Assets

$6.4B

Total Liabilities

$1.8B

Stockholders' Equity

$4.6B

Cash & Equivalents

$725M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.1B	$1.8B	+13.5%
Gross Profit	$1.6B	$1.4B	+15.8%
Operating Income	$161M	-$82M	+295.5%
Net Income	$142M	-$64M	+320.9%